Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrödinger, Inc. (Nasdaq: SDGR) is a computational science company focused on transforming molecular discovery for drug development and materials design. Its news flow reflects activity across software, collaborations, financial performance and a growing therapeutics portfolio, giving investors and industry observers insight into how its physics+AI platform is being applied in practice.
Recent press releases highlight progress in advancing Schrödinger’s physics+AI computational platform, including a predictive toxicology initiative, an AI-powered conversational interface in its Maestro graphical environment, and integration of Lilly’s TuneLab platform into LiveDesign, its cloud-native enterprise informatics environment. These updates illustrate how the company combines physics-based simulations with AI and machine learning to address challenges such as data scarcity in drug discovery.
Schrödinger’s news also covers collaborations and co-founded companies. Examples include expanded research agreements with Ajax Therapeutics, Lilly and Otsuka Pharmaceutical, as well as developments from Nimbus, Structure Therapeutics and Copernic Catalysts, all of which use Schrödinger’s platform in different ways. News items have described positive data for molecules such as zasocitinib, co-invented by Schrödinger and Nimbus, and the creation of a new ammonia synthesis catalyst in collaboration with Copernic.
On the corporate side, SDGR news includes quarterly financial results, updated financial guidance, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Pipeline updates for proprietary programs such as SGR-1505, SGR-3515, SGR-5573 and SGR-6016 appear alongside platform and partnership announcements, providing a combined view of software and drug discovery activities.
Investors and researchers can use the SDGR news page to follow earnings releases, platform enhancements, regulatory designations, collaborative milestones and governance disclosures that shape the company’s trajectory.
Schrödinger (SDGR) has granted restricted stock units (RSUs) for 5,445 shares of common stock to five newly hired employees on February 17, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule: 25% vests after 12 months of continuous service from the vesting commencement date, followed by the remaining balance vesting in three equal yearly installments of 25% each. These inducement grants are governed by award agreements and the company's 2021 Inducement Equity Incentive Plan.
Schrödinger (Nasdaq: SDGR) has announced it will release its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results. Investors can access the live webcast through the company's website's 'Investors' section, where it will remain available for approximately 90 days.
Schrödinger (SDGR) has granted restricted stock units (RSUs) for 4,840 shares of common stock to four newly hired employees on January 20, 2025. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule: 25% vests after 12 months of continuous service from the vesting commencement date, followed by the remaining balance vesting in three equal yearly installments of 25% each. These inducement grants are governed by award agreements and the company's 2021 Inducement Equity Incentive Plan.
Schrödinger provided an update on its 2024 progress and outlined its 2025 strategic priorities. Key highlights include:
Expanded Collaborations: Schrödinger expanded its research collaboration with Otsuka Pharmaceutical Co., , and its agreement with Novartis, which includes a $150 million upfront payment expected in Q1 2025.
2024 Achievements: The company launched initiatives to enhance its computational platform and introduced LiveDesign Biologics. It published 29 peer-reviewed articles and advanced Phase 1 clinical studies for SGR-1505, SGR-2921, and SGR-3515. The FDA granted Fast Track Designation to SGR-2921.
Collaborations and Investments: Schrödinger announced a $150 million collaboration with Novartis, with potential milestone payments of up to $2.3 billion. Co-founded companies, including Morphic Holding and Ajax Therapeutics, made significant progress in their respective fields.
2025 Strategic Priorities: Schrödinger aims to increase customer adoption of its technology, advance predictive toxicology, and present initial Phase 1 data for SGR-1505, SGR-2921, and SGR-3515.
Schrödinger will release its Q4 and full-year financial results on February 26, 2025.
Schrödinger (SDGR) has granted restricted stock units (RSUs) for 8,365 shares to six newly hired employees on December 12, 2024. The grants were made under the company's 2021 Inducement Equity Incentive Plan and approved by the compensation committee. The RSUs will vest over four years, with 25% vesting after 12 months of continuous service, followed by equal yearly installments of 25% over the next three years. These grants serve as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Schrödinger (Nasdaq: SDGR) has announced its upcoming participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, December 4, 2024, at 8:30 a.m. ET. Interested parties can access the live webcast through the 'Investors' section of Schrödinger's website, where it will remain available for approximately 90 days after the event.
Schrödinger (SDGR) has granted restricted stock units (RSUs) for 2,785 shares to four new employees as inducement awards. The grants, made under the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs follow a four-year vesting schedule, with 25% vesting after 12 months of continuous service and the remaining 75% vesting in equal yearly installments over the following three years.
Schrödinger (SDGR) is expanding its computational platform initiative to predict toxicology risk in early drug discovery, receiving an additional $9.5 million from the Bill & Melinda Gates Foundation, following their initial $10 million grant in July 2024. The funding extends to April 2026 and will accelerate access to experimental structures. The technology aims to reduce drug development failures by identifying off-target protein binding risks. Once developed, the tools will be available to Gates Foundation grantees globally and Schrödinger's software customers, supporting drug development for diseases affecting low- and middle-income countries.
Schrödinger (SDGR) reported Q3 2024 financial results with total revenue of $35.3 million, down from $42.6 million in Q3 2023. Software revenue increased 10% to $31.9 million, while drug discovery revenue decreased to $3.4 million. The company announced a new collaboration with Novartis, receiving $150 million upfront with potential milestone payments up to $2.3 billion. Operating expenses rose to $86.2 million, and net loss was $38.1 million. The company updated its 2024 guidance, projecting software revenue growth of 8-13% and drug discovery revenue between $20-30 million.
Schrödinger (SDGR) has announced a significant collaboration with Novartis comprising two major agreements. First, a research collaboration and license agreement where Schrödinger will receive $150 million upfront and is eligible for up to $2.3 billion in milestone payments plus royalties. Second, an expanded three-year software agreement giving Novartis broader access to Schrödinger's computational predictive modeling technology.
The companies will jointly work on multiple development candidates in Novartis's core therapeutic areas. While both companies will share discovery responsibilities, Novartis will handle clinical development, manufacturing, and global commercialization. The royalty structure includes tiered mid single-digit to low double-digit percentages on net sales.